# Impact of Liraglutide 3.0 on Body Fat Distribution

> **NCT03038620** · PHASE4 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 235 (actual)

## Conditions studied

- Obesity, Visceral
- Cardiovascular Diseases
- Fat Disorder

## Interventions

- **DRUG:** Liraglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03038620
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2020-10-13
- **Final completion:** 2020-10-13
- **Target enrollment:** 235 (ACTUAL)
- **Last updated:** 2021-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03038620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03038620, "Impact of Liraglutide 3.0 on Body Fat Distribution". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03038620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*